Immune modulatory activity of ribavirin for serious human metapneumovirus disease: early i.v. therapy may improve outcomes in immunosuppressed SCT recipients

Safdar, Amar

doi:10.1038/bmt.2008.80

Cited by 28 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Till now a lot of experience on treatment of HMPV has been gained in individual cases and small case series [120,122,140,141,142]. The combination of ribavirin with IVIG seems to be very promising, although this combination is expensive and has disadvantages.…”

Section: Discussionmentioning

confidence: 99%

Human Metapneumovirus in Adults

Haas

Thijsen

Elden

et al. 2013

Viruses

View full text Add to dashboard Cite

Human metapneumovirus (HMPV) is a relative newly described virus. It was first isolated in 2001 and currently appears to be one of the most significant and common human viral infections. Retrospective serologic studies demonstrated the presence of HMPV antibodies in humans more than 50 years earlier. Although the virus was primarily known as causative agent of respiratory tract infections in children, HMPV is an important cause of respiratory infections in adults as well. Almost all children are infected by HMPV below the age of five; the repeated infections throughout life indicate transient immunity. HMPV infections usually are mild and self-limiting, but in the frail elderly and the immunocompromised patients, the clinical course can be complicated. Since culturing the virus is relatively difficult, diagnosis is mostly based on a nucleic acid amplification test, such as reverse transcriptase polymerase chain reaction. To date, no vaccine is available and treatment is supportive. However, ongoing research shows encouraging results. The aim of this paper is to review the current literature concerning HMPV infections in adults, and discuss recent development in treatment and vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%

Human Metapneumovirus in Adults

Haas

Thijsen

Elden

et al. 2013

Viruses

View full text Add to dashboard Cite

show abstract

“…Although the natural course of this disease can be associated with full recovery, children may have severe disseminated disease with poor outcomes (12), as well as immunocompromised patients (10), who may benefit from early intervention (13). To date, there are no trials examining specific treatments for hMPV.…”

Section: Discussionmentioning

confidence: 99%

The human metapneumovirus: a case series and review of the literature

Shahda

Carlos

Kiel

et al. 2010

Transplant Infectious Dis

View full text Add to dashboard Cite

Human metapneumovirus (hMPV) is an emerging human pulmonary pathogen that is genetically related to respiratory syncytial virus. It has been increasingly associated with respiratory illnesses over the last few decades. Immunocompromised patients are particularly susceptible with resultant morbidity and mortality. We describe our experience with 9 immunocompromised patients diagnosed with pneumonia secondary to hMPV, 2 of whom were successfully treated with aerosolized and oral ribavirin along with intravenous immunoglobulin (IVIG).We suggest that hMPV should be considered in the differential diagnosis of immunocompromised patients with acute respiratory illness. Ribavirin (oral and aerosolized) with IVIG is potentially an effective treatment option for those with severe disease.

show abstract

“…[70][71][72] As well, there are reports of successful treatment of human cases with ribavirin with or without concomitant immune globulin. [73][74][75] Candidate vaccines for hMPV are being investigated in animal models. 76,77 CoV Including SARS CoV…”

Section: Human Metapneumovirusmentioning

confidence: 99%

Respiratory Viral Infections in Transplant and Oncology Patients

Kumar

Humar

2010

Infectious Disease Clinics of North America

View full text Add to dashboard Cite

Respiratory viral infections are a significant cause of morbidity and mortality in the immunocompromised host. In the last two decades, there has been significant advancement in the epidemiology and laboratory diagnosis of respiratory viral infections. In addition, the clinical consequences of many respiratory viruses in the immunocompetent and immunocompromised host continue to be studied. Many therapeutics have also now become available, although their efficacy in transplant recipients remains uncertain. This article describes the current knowledge about respiratory viral infections as it relates to solid organ transplant, hematopoietic stem cell transplant, and oncology settings.

show abstract

Immune modulatory activity of ribavirin for serious human metapneumovirus disease: early i.v. therapy may improve outcomes in immunosuppressed SCT recipients

Cited by 28 publications

References 10 publications

Human Metapneumovirus in Adults

Human Metapneumovirus in Adults

The human metapneumovirus: a case series and review of the literature

Respiratory Viral Infections in Transplant and Oncology Patients

Contact Info

Product

Resources

About